Skip to main content

ABVX · Abivax S.A.

Track ABVX — free
$71.69 -8.96 (-11.11%)
Market Cap
$7.06B
Shares
87.54M
Volume · Nov 20 11M Avg daily vol (3M) 1.13M

Price & Indicators

 

Key stats

Close
$80.65
Thu 19 Nov
Open
$83.73
Thu 19 Nov
Average volume, 30 days
956K
shares a session
Short interest
4.1M
4.7% of shares · 4.6 days to cover
Day range
$80.17$86.93
Open $83.73 Close $80.65
52-week closing range
$72.50$145.31
Close $80.65 44.5% under the high
Short volume, last session
55%
Last earnings
Sep 21, 2026
Price history
Oct 2023 to Nov 2026

Up next

Dec 14, 2026 Scheduled · in 3 wks
call held Jan 25, 2024

Latest documents

2026
Nov 9
Investor event
50% maintenance remission, filing by end of year

Abivax said 50% of patients achieved endoscopic remission at the end of maintenance and plans to file by the end of the year, with one batch submitted 30 days later without changing the review timetable.

3 source passages
It is my pleasure to welcome our next presenting company, Abivax. one of our endpoints, endoscopic remission, is basically 50% of our patients are in endoscopic remission at the end of maintenance So we're filing by the end of the year and what we agreed with FDA at the pre-NDA meeting was that one of our batches needed another month of stability data. So they agreed to allow us to submit that 30 days later after the NDA submission and have no change in the clock for the PDUFA date. Open the document at this passage
Sep 21
Current report 6-K
Current report

Abivax SA reported a €165.9 million net loss for the six months ended June 30, 2026, completed a July 2026 ADS offering generating approximately $874.1 million in net proceeds, and said liquidity would fund operations for at least 12 months.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.87M
Trailing 12 months
Net income (TTM)
−$467.93M
Trailing 12 months
Revenue growth YoY
+9.9%
Year over year
Operating margin
-5,821.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.0%
Year over year · more shares
Price change (1Y)
-28.6%
Trailing year
Short interest
4.7%
Latest settlement · 4.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −28%
below
Price vs 50-day avg −12%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −11%
trailing
6-month return −38%
trailing
YTD return −40%
this year
Relative strength −32%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $92 › 200d $112 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +63 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.70% of shares out · ▼ -43.3% MoM · 4.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
323 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −50%
past year
ATR 5.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−28% Bearish
Price vs 50-day avg
−12% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $92 › 200d $112 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +63 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.70% of shares out · ▼ -43.3% MoM · 4.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
323 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $73 Now $81 · 11% Range high $145
vs 200-day avg -28% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABVX
Abivax S.A.
this stock
$7.06B -40.2% — — 4.7%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
323
% held
65.2%
Net QoQ
+2.1M sh
Top holder
Helikon Investments Ltd
Held Float
View
Held by Funds
Fund positions
89
View
Short & Settlement
Short Interest Falling
Shares short
4.1M
Days to cover
4.6d
Change
-3.1M sh
View
Short Volume
Short vol %
55%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3.3K
Value
$293.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
46.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 9, 2026
This year
13

Abivax said 50% of patients achieved endoscopic remission at the end of maintenance and plans to file by the end of the year, with one batch submitted 30 days later without changing the review timetable.

View
Proposed Sales
Value
$133.7M
Shares
1.0M
Filed
Jan 8, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 30, 2026
Last webcast
Nov 9, 2026
View
Investor Relations
Upcoming events
4
View

Performance

5D 20D 120D MTD YTD
ABVX -10.6% -10.6% -37.8% -6.9% -40.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -5.1% -4.3% -32.2% -1.6% -45.2%
Key facts CIK 1956827 CUSIP 00370M103 13F (30d) 308 filings 297 filers Visit website Investor relations